SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Bezlotoxumab Formulation

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier
   Trade name : Bezlotoxumab Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against
   Use of the Substance/Mixture : Pharmaceutical

1.3 Details of the supplier of the safety data sheet
   Company : MSD
   Shotton Lane
   NE23 3JU Cramlington NU - Great Britain
   Telephone : 44 1 670 59 30 00
   Telefax : 908-735-1496
   E-mail address of person responsible for the SDS: EHSDATASTEWARD@msd.com

1.4 Emergency telephone number
   1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture
   Classification (REGULATION (EC) No 1272/2008)
   Not a hazardous substance or mixture.

2.2 Label elements
   Labelling (REGULATION (EC) No 1272/2008)
   Not a hazardous substance or mixture.

2.3 Other hazards
   None known.

SECTION 3: Composition/information on ingredients

3.2 Mixtures
   Components

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>EC-No.</th>
<th>Index-No.</th>
<th>Registration number</th>
<th>Classification</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
</table>
SECTION 4: First aid measures

4.1 Description of first aid measures

Protection of first-aiders: No special precautions are necessary for first aid responders.

If inhaled: If inhaled, remove to fresh air. Get medical attention if symptoms occur.

In case of skin contact: Wash with water and soap as a precaution. Get medical attention if symptoms occur.

In case of eye contact: Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.

If swallowed: If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

None known.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment: Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media: Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media: None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during firefighting: Exposure to combustion products may be a hazard to health.

Hazardous combustion products: Carbon oxides

5.3 Advice for firefighters

Special protective equipment: Wear self-contained breathing apparatus for firefighting if nec-
SAFETY DATA SHEET
generated according to Regulation (EC) No. 1907/2006

Bezlotoxumab Formulation


for firefighters

Specific extinguishing methods:
Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures
Personal precautions:
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions
Environmental precautions:
Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g. by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up
Methods for cleaning up:
Soak up with inert absorbent material.
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyed material can be pumped, store recovered material in appropriate container.
Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections
See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling
Technical measures:
See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
Local/Total ventilation:
Use only with adequate ventilation.
Advice on safe handling:
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.
Take care to prevent spills, waste and minimize release to the environment.

**Hygiene measures**: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

### 7.2 Conditions for safe storage, including any incompatibilities

**Requirements for storage areas and containers**: Keep in properly labelled containers. Store in accordance with the particular national regulations.

**Advice on common storage**: Do not store with the following product types:

- Strong oxidizing agents

### 7.3 Specific end use(s)

**Specific use(s)**: No data available

---

### SECTION 8: Exposure controls/personal protection

#### 8.1 Control parameters

**Occupational Exposure Limits**

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bezlotoxumab</td>
<td>1246264-45-8</td>
<td>TWA</td>
<td>2 mg/m3 (OEB 1)</td>
<td>Internal</td>
</tr>
</tbody>
</table>

**8.2 Exposure controls**

**Engineering measures**

Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Laboratory operations do not require special containment.

**Personal protective equipment**

**Eye protection**: Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

**Hand protection**

**Material**: Chemical-resistant gloves

**Skin and body protection**: Work uniform or laboratory coat.
Bezlotoxumab Formulation

Respiratory protection: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection. Equipment should conform to NS EN 143

Filter type: Particulates type (P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Appearance: Aqueous solution
Colour: Colorless to pale yellow
Odour: No data available
Odour Threshold: No data available
pH: 5,7 - 6,3
Melting point/freezing point: No data available
Initial boiling point and boiling range: No data available
Flash point: No data available
Evaporation rate: No data available
Flammability (solid, gas): Not applicable
Upper explosion limit / Upper flammability limit: No data available
Lower explosion limit / Lower flammability limit: No data available
Vapour pressure: No data available
Relative vapour density: No data available
Relative density: No data available
Density: 1,0146 g/cm3
Solubility(ies)
Water solubility: No data available
Partition coefficient: n-octanol/water: Not applicable
Auto-ignition temperature: No data available
Decomposition temperature: No data available
Viscosity
Viscosity, dynamic: 1,2 mPa.s (25 °C)
Viscosity, kinematic: 1,833 mm2/s (4 °C)
Bezlotoxumab Formulation

Explosive properties: Not explosive
Oxidizing properties: The substance or mixture is not classified as oxidizing.

9.2 Other information
- Flammability (liquids): No data available
- Molecular weight: No data available
- Particle size: Not applicable

SECTION 10: Stability and reactivity

10.1 Reactivity
- Not classified as a reactivity hazard.

10.2 Chemical stability
- Stable under normal conditions.

10.3 Possibility of hazardous reactions
- Hazardous reactions: Can react with strong oxidizing agents.

10.4 Conditions to avoid
- Conditions to avoid: None known.

10.5 Incompatible materials
- Materials to avoid: Oxidizing agents

10.6 Hazardous decomposition products
- No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on toxicological effects
- Information on likely routes of exposure:
  - Inhalation
  - Skin contact
  - Ingestion
  - Eye contact

Acute toxicity
- Not classified based on available information.

Components:
- Bezlotoxumab:
  - Acute toxicity (other routes of administration): LD50 (Mouse): > 125 mg/kg
    - Application Route: Intravenous
    - Remarks: No adverse effect has been observed in acute tox-
Bezlotoxumab Formulation

Skin corrosion/irritation
Not classified based on available information.

Serious eye damage/eye irritation
Not classified based on available information.

Respiratory or skin sensitisation
Skin sensitisation
Not classified based on available information.

Respiratory sensitisation
Not classified based on available information.

Germ cell mutagenicity
Not classified based on available information.

Carcinogenicity
Not classified based on available information.

Reproductive toxicity
Not classified based on available information.

STOT - single exposure
Not classified based on available information.

STOT - repeated exposure
Not classified based on available information.

Repeated dose toxicity

Components:

Bezlotoxumab:
Species : Mouse
NOAEL : 50 mg/kg
Application Route : Intravenous
Exposure time : 15 d
Remarks : No significant adverse effects were reported

Species : Mouse
NOAEL : 125 mg/kg
Application Route : Intravenous
Exposure time : 21 d
Remarks : No significant adverse effects were reported

Aspiration toxicity
Not classified based on available information.

Experience with human exposure

Components:
Bezlotoxumab:
Bezlotoxumab Formulation

**SECTION 12: Ecological information**

12.1 Toxicity  
No data available

12.2 Persistence and degradability  
No data available

12.3 Bioaccumulative potential  
No data available

12.4 Mobility in soil  
No data available

12.5 Results of PBT and vPvB assessment  
Not relevant

12.6 Other adverse effects  
No data available

**SECTION 13: Disposal considerations**

13.1 Waste treatment methods  
Product: Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.

Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

**SECTION 14: Transport information**

14.1 UN number  
Not regulated as a dangerous good

14.2 UN proper shipping name  
Not regulated as a dangerous good

14.3 Transport hazard class(es)  
Not regulated as a dangerous good

14.4 Packing group  
Not regulated as a dangerous good

14.5 Environmental hazards  
Not regulated as a dangerous good

14.6 Special precautions for user  
Not applicable

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Bezłotoxumab Formulation


Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, preparations and articles (Annex XVII) : Not applicable
REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59). : Not applicable
REACH - List of substances subject to authorisation (Annex XIV) : Not applicable
Regulation (EC) No 1005/2009 on substances that deplete the ozone layer : Not applicable
Regulation (EU) 2019/1021 on persistent organic pollutants (recast) : Not applicable
Regulation (EC) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals : Not applicable

The components of this product are reported in the following inventories:
AICS : not determined
DSL : not determined
IECSC : not determined

15.2 Chemical safety assessment
A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of other abbreviations

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AIIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - Interna-
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Bezlotoxumab Formulation

Version: 1.12
Revision Date: 25.09.2020
SDS Number: 818324-00013
Date of last issue: 16.09.2020
Date of first issue: 22.07.2016

Further information

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

NO / EN